ProCE Banner Activity

AZD0486, a CD19 x CD3 Bispecific Antibody, for Relapsed/Refractory Follicular Lymphoma

Conference Coverage
Slideset

Data from a phase I study demonstrated activity with the CD19 x CD3 bispecific antibody AZD0486 in patients with relapsed/refractory follicular lymphoma with ≥2 prior lines of therapy, with deep responses and acceptable tolerability with a double step-up dosing schedule.

Released: December 09, 2024

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation